Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.
Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A. Provencio M, et al. Leuk Lymphoma. 2019 Mar;60(3):856-859. doi: 10.1080/10428194.2018.1509322. Epub 2018 Sep 20. Leuk Lymphoma. 2019. PMID: 30234403 No abstract available.
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
Provencio M, Sabín P, Gomez-Codina J, Torrente M, Calvo V, Llanos M, Gumá J, Quero C, Blasco A, Cruz MA, Aguiar D, García-Arroyo F, Lavernia J, Martinez N, Morales M, Saez-Cusi A, Rodriguez D, de la Cruz L, Sanchez JJ, Rueda A; GOTEL (Spanish Lymphoma Oncology Group). Provencio M, et al. PLoS One. 2017 May 11;12(5):e0177204. doi: 10.1371/journal.pone.0177204. eCollection 2017. PLoS One. 2017. PMID: 28493986 Free PMC article.
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR, de la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A; Gotel (Spanish Lymphoma Oncology Group). Provencio M, et al. Leuk Lymphoma. 2014 Jan;55(1):51-5. doi: 10.3109/10428194.2013.790544. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23573825 Clinical Trial.
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, Alvarez R, Martinez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, Provencio M. Rueda A, et al. Leuk Lymphoma. 2019 Jun;60(6):1576-1579. doi: 10.1080/10428194.2018.1542147. Epub 2018 Dec 5. Leuk Lymphoma. 2019. PMID: 30516082 Clinical Trial. No abstract available.
High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma.
Rueda A, Rifá J, Quero C, Gómez-Codina J, Murias A, García-Arroyo FR, Sabín P, Llanos M, Herrero J, Lobo F, Delgado JR, Provencio M; Spanish Lymphoma Oncology Group. Rueda A, et al. Leuk Lymphoma. 2014 Jun;55(6):1413-6. doi: 10.3109/10428194.2013.836601. Epub 2013 Oct 9. Leuk Lymphoma. 2014. PMID: 23964649 No abstract available.
Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
Provencio M, Royuela A, Torrente M, Pollán M, Gómez-Codina J, Sabín P, Llanos M, Gumá J, Quero C, Blasco A, Aguiar D, García-Arroyo FR, Lavernia J, Martínez N, Morales M, Saenz-Cusi Á, Rodríguez D, Calvo V, de la Cruz-Merino L, de la Cruz MÁ, Rueda A; Spanish Lymphoma Oncology Group. Provencio M, et al. Cancer. 2017 Oct 1;123(19):3709-3716. doi: 10.1002/cncr.30795. Epub 2017 Jun 13. Cancer. 2017. PMID: 28608996 Free article.
Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?
Provencio M, Sabín P, Gómez Codina J, Rueda A, Llanos M, Gumá J, Quero Blanco C, Blasco A, Delgado JR, Cruz MÁ, Aguiar D, García-Arroyo FR, Herrero J, Lavernia J, Martínez Banaclocha N, Morales M, Fuster J, Sáez Cusi Á, Lobo F, Rodríguez Abreu D, de la Cruz L, Antón E, Rodríguez Jiménez A, Arízcun A, Pérez X; GOTEL (Spanish Lymphoma Oncology Group). Provencio M, et al. Clin Transl Oncol. 2012 May;14(5):386-90. doi: 10.1007/s12094-012-0813-3. Clin Transl Oncol. 2012. PMID: 22551546
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, Martín-Acosta P, Gómez S, González-Rincón J, Santos A, Tarin C, García JF, García-Arroyo FR, Rueda A, Camacho FI, García-Cosío M, Heredero A, Llanos M, Mollejo M, Piris-Villaespesa M, Gómez-Codina J, Yanguas-Casás N, Sánchez A, Piris MA, Provencio M, Sánchez-Beato M. Pedrosa L, et al. Sci Rep. 2021 Jan 21;11(1):1886. doi: 10.1038/s41598-020-80376-0. Sci Rep. 2021. PMID: 33479306 Free PMC article.
Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.
Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, Aguiar D, Gumá J, Blanco CQ, García Arroyo FR, Garitaonaindia Y, Provencio Z, Calvo V, González-San Segundo C, Provencio M. Núñez-García B, et al. Hematol Oncol. 2021 Oct;39(4):506-512. doi: 10.1002/hon.2835. Epub 2021 Feb 2. Hematol Oncol. 2021. PMID: 33528063
60 results